Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- DSP to Merge Its Clinical Development Functions with US Subsidiary’s
March 6, 2013
- Ranbaxy Resumes Production of Atorvastatin at US Plant
March 6, 2013
- 2 SGLT-2 Inhibitors to Be Filed for Approval without Concurrent-Use Restrictions
March 5, 2013
- Pfizer Positive about In-Licensing Other Firms’ Long-Listed Drugs: VP Matsumori
March 5, 2013
- 3-Drug H. pylori Eradication Therapies to Get Further Indication for Chronic Gastritis; Big Boost to PPI Market Expected
March 5, 2013
- Daiichi Sankyo to Set Up Biologics Oversight Function within R&D Division in Order to Enhance Biopharmaceutical Research Level
March 5, 2013
- Teva Pharma, Nippon Kayaku Receive Approval of Japan’s Second G-CSF Biosimilar
March 5, 2013
- Announcement: 6th annual Marketing Excellence Japan 2013 – Hilton Tokyo, May 14 – 15
March 4, 2013
- Pfizer Japan’s Ethical Drug Sales Dip 4.2% on Lipitor Patent Expiry: FY2012 Earnings
March 4, 2013
- Extra Concurrent-Use Indications Approved for DPP-4 Inhibitor Equa: Novartis
March 4, 2013
- Merck Serono Appoints Koichi Katsura as Head of R&D Japan
March 4, 2013
- Abilify Once-Monthly Injection Approved in US: Otsuka
March 4, 2013
- ARB Sales Apparently Peak Out in Japan Antihypertensive Market
March 1, 2013
- Astellas to Adopt International Financial Reporting Standards as of March 2014
March 1, 2013
- DSP’s US Subsidiary Sunovion Announces FDA Acceptance of NDA Resubmission for Epilepsy Treatment Stedesa
March 1, 2013
- Takeda to Develop New Compounds for Autoimmune Diseases Jointly with Resolve Therapeutics of US
March 1, 2013
- Taiho Files for Novel Anticancer Agent TAS-102 in Japan
March 1, 2013
- BMKK, Pfizer Japan Launch, Copromote Anti-Xa Agent Eliquis
March 1, 2013
- Shionogi Receives FDA Approval for Dyspareunia Treatment, Plans its Launch in June
February 28, 2013
- Gilenya Achieved Blockbuster Status in 2012; Canagliflozin Will Be Next: Pres. Tsuchiya of MTPC
February 28, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…